CinnoVex is the trade name of recombinant Interferon beta 1-a, which is manufactured as biosimilar in Iran.
Contents |
An interferon-beta protein developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart, Germany, in collaboration with CinnaGen company, Tehran, Iran, is now the first therapeutic protein from a Fraunhofer laboratory to be approved as biogeneric / biosimilar medicine.
Interferon-beta is used for multiple sclerosis (MS) therapy. Multiple sclerosis is the most common disease of the central nervous system. Estimates put the number of people suffering from multiple sclerosis at about 2.5 million worldwide. The most common therapeutic treatment so far is with interferon-beta, a protein produced naturally in the body. It slows down the progression of the illness and reduces the relapse rate. Biotechnological techniques make it possible to engineer this endogenous protein in mammalian cells.
An interferon-beta-1a, whose biotechnical engineering and production up to the pilot scale was optimized at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in collaboration with CinnaGen Company, has now been approved as biogeneric by the Iranian Food and Drug Administration (IFDA).
CinnoVex is a glycoprotein and a Cytokine. Interferon beta 1-a is a 22,500 Da glycoprotein, which has antiviral activity and regulates the immune system of the human body.
CinnoVex is available as powder in 2 ml vials along with injectable distilled water. Each dose contains 30 micrograms of active protein which is equal to 6 million international unit of activity. It should be injected intramuscularly.
Press release of Fraunhofer institute (IGB)
Drug brochure of CinnoVex